Overview

The Effects of Intravitreal Ozurdex Implant in DME

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Intravitreal Ozurdex implant therapy improves visual outcome and OCT findings. The purpose of this study is that these results are correlated with the change of cytokine level known to be increased in DME patients.
Phase:
Phase 4
Details
Lead Sponsor:
Nune Eye Hospital, Seoul, Korea
Treatments:
BB 1101
Dexamethasone
Dexamethasone acetate